We are live on ! Find out more
SBFM

Sunshine Biopharma

3 hedge funds and large institutions have $111K invested in Sunshine Biopharma in 2024 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

24% more capital invested

Capital invested by funds: $89.6K → $111K (+$21.7K)

0.28% more ownership

Funds ownership: 0.01%0.29% (+0.28%)

63% less funds holding

Funds holding: 83 (-5)

71% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 7

Holders
3
Holders Change
-5
Holders Change %
-62.5%
% of All Funds
0.04%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
2
Increased
1
Reduced
Closed
7
Calls
Puts
Net Calls
Net Calls Change

SBFM Hedge Fund Activity: Q3 2024 in Review

3 of the 6,965 institutional investors tracked by Wall St. Rank reported a position in Sunshine Biopharma (SBFM) for Q3 2024, worth a combined $111K — up 24% from $89.6K a quarter earlier.

Sellers outnumbered buyers: 7 funds closed out of SBFM and 2 opened new positions — a net loss of 5 holders — while 0 trimmed existing stakes and 1 added.

The largest buyer was Bank of America, adding an estimated $147K. The largest seller was Susquehanna International Group, exiting entirely with an estimated $32.1K sold.

  • 3 institutional investors held Sunshine Biopharma (SBFM) as of Q3 2024, down from 8 in Q2 2024.
  • Funds reported $111K of Sunshine Biopharma stock for Q3 2024, up 24% quarter-over-quarter.
  • 2 funds opened new Sunshine Biopharma positions in Q3 2024 and 7 closed out, a net change of -5 holders.
  • The largest Sunshine Biopharma buyer in Q3 2024 was Bank of America, an estimated $147K added.
  • The largest Sunshine Biopharma seller in Q3 2024 was Susquehanna International Group, an estimated $32.1K sold.

Based on aggregated 13F filings for Q3 2024.